GLP-1 Medications May Quiet the Craving Behind Addiction
A landmark BMJ study published June 3, 2026 found that GLP-1 receptor agonists like semaglutide significantly reduced both the development and severity of substance use disorders in over 600,000 U.S. veterans. Cannabis use disorder risk dropped 14%,…
Emerging Clinical Data on GLP-1 Receptor Agonists in Alcohol Use Disorder
GLP-1 receptor agonist alcohol use disorder clinical data reveals potential therapeutic effects beyond glycemic control. This emerging evidence suggests benefits in craving reduction and reward pathway modulation. Family medicine clinicians should…
CBD gummies to quit smoking cigarettes reddit
While online discussions promote CBD gummies smoking cessation clinical evidence, current research remains limited to small studies with mixed results. The theoretical mechanisms are promising, but proven cessation therapies should remain first-line…
GLP-1 Drugs for Alcohol Cravings: Clinical Evidence Review
Tirzepatide alcohol cravings reduction is an emerging clinical focus in addiction medicine. This review examines the evidence supporting tirzepatide's effects on alcohol use disorder. Understanding this dual GLP-1/GIP agonist's impact may improve…
Oral Semaglutide and Medicare Coverage: Expanding GLP-1 Access
Oral semaglutide Medicare coverage is expanding access to GLP-1 therapy for patients seeking weight management options. This oral formulation offers an alternative to injections, improving adherence. Understanding Medicare Part D coverage is essential…
GLP-1 Receptor Agonists for Addiction: Clinical Evidence and Insights
GLP-1 receptor agonists addiction medicine is an emerging field showing potential to modulate addictive behaviors. Clinical evidence suggests these agents influence dopamine pathways affecting substance use. Understanding this can aid clinicians in…
Clinical Evidence on Semaglutide for Alcohol Consumption Reduction
Semaglutide alcohol consumption reduction shows promise in clinical trials for patients with alcohol use disorder. This GLP-1 receptor agonist may help reduce heavy drinking days and overall alcohol intake. Understanding this effect is important for…
Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.
New expert consensus guidelines include evidence-based recommendations for cannabis use disorder treatment alongside other substance dependencies. The British Association for Psychopharmacology guidelines provide clinicians with systematic approaches to…
Effectiveness and clinical predictors of a virtual based combined cognitive behavioral and motivational enhancement group therapy for adults with cannabis use disorder.
A retrospective study of 116 adults found that virtual cannabis use disorder treatment using CBT-MET produced significant improvements in cannabis use frequency and related symptoms. The 12-week virtual group program demonstrated clinical effectiveness…
A qualitative study on cannabis use for harm reduction and pain among veterans enrolled in an SUD treatment program.
A qualitative study reveals how veterans with substance use disorders view cannabis for veteran chronic pain management. Veterans reported using cannabis to manage chronic pain, anxiety, and sleep issues during addiction treatment. This research…